Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Prostate Carcinoma”

406 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 406 results

Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Testing effectiveness (Phase 2)Study completedNCT00284752
What this trial is testing

Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Kaiser Permanente 56
Testing effectiveness (Phase 2)Study completedNCT01215799
What this trial is testing

Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
CytRx 23
Testing effectiveness (Phase 2)Study completedNCT00201357
What this trial is testing

An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

Who this might be right for
Hormone-refractory Prostate Cancer
National Health Research Institutes, Taiwan 30
Testing effectiveness (Phase 2)Study completedNCT00082134
What this trial is testing

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

Who this might be right for
Hormone-refractory Prostate Cancer
Genzyme, a Sanofi Company 40
Testing effectiveness (Phase 2)Study completedNCT00257478
What this trial is testing

The Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Who this might be right for
Prostate CancerCancer of ProstateProstatic Cancer+1 more
Astellas Pharma Inc
Testing effectiveness (Phase 2)Looking for participantsNCT04503265
What this trial is testing

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant NeoplasmBreast CancerOvarian Cancer+3 more
AtlasMedx, Incorporated 122
Testing effectiveness (Phase 2)UnknownNCT00024414
What this trial is testing

DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Theradex
Testing effectiveness (Phase 2)Study completedNCT00025116
What this trial is testing

ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
NCIC Clinical Trials Group 40
Testing effectiveness (Phase 2)Study completedNCT00278993
What this trial is testing

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Who this might be right for
Prostate Cancer
Eisai Inc. 108
Testing effectiveness (Phase 2)UnknownNCT04586543
What this trial is testing

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

Who this might be right for
Metastatic Castration-resistant Prostate CancerAdenocarcinoma of the Prostate
László Mangel 110
Testing effectiveness (Phase 2)UnknownNCT00003183
What this trial is testing

Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Hope Cancer Institute, Inc. 64
Testing effectiveness (Phase 2)Study completedNCT00476645
What this trial is testing

Fulvestrant in Hormone Refractory Prostate Cancer

Who this might be right for
Prostatic NeoplasmsProstate Cancer
Stanford University 10
Testing effectiveness (Phase 2)Ended earlyNCT04754425
What this trial is testing

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted AgentsMetastatic Malignant Neoplasm in the Bone+5 more
M.D. Anderson Cancer Center 11
Testing effectiveness (Phase 2)Study completedNCT00895310
What this trial is testing

Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy

Who this might be right for
Prostate Cancer
University of California, Davis 30
Large-scale testing (Phase 3)Ended earlyNCT00676650
What this trial is testing

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Who this might be right for
Prostatic Neoplasms
Pfizer 873
Testing effectiveness (Phase 2)Study completedNCT00554918
What this trial is testing

Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy

Who this might be right for
Metastatic CancerProstate Cancer
University Hospital Birmingham 300
Testing effectiveness (Phase 2)Ended earlyNCT03577028
What this trial is testing

Study of HPN424 in Patients With Advanced Prostate Cancer

Who this might be right for
Advanced Prostate Cancer
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 104
Testing effectiveness (Phase 2)UnknownNCT00448734
What this trial is testing

Picoplatin and Docetaxel in Subjects With Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
Poniard Pharmaceuticals 95
Early research (Phase 1)Study completedNCT01460134
What this trial is testing

CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Who this might be right for
CD27 Expressing B-cell Malignancies for Example Hodgkin's LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+7 more
Celldex Therapeutics 90
Load More Results